Dr Neil Love has been involved with breast cancer treatment, research and education since 1975, when he joined the University of Miami Comprehensive Cancer Center in the division of medical oncology. After 10 years as a practicing medical oncologist, Dr Love’s interests shifted from direct patient care towards oncology education, and he founded Research To Practice, a medical education company with a targeted niche focused on the integration of research leader perspectives into oncology practice. The impetus for this shift was Dr Love’s observation as a university faculty member that many effective oncology strategies utilized by physicians in academia were underutilized in community practice.

In 1988, Dr Love launched the Breast Cancer Update audio series to “bridge the gap between research and patient care.” Dr Love’s prediction that providing research leader opinions to community physicians would dramatically alter practice patterns has been borne out. Extensive market research, analysis and experience have proven that this educational model is extremely effective, practical and well liked among the target audience.

In recent years, RTP has expanded the model to include the many constituents comprising the oncology community. Acting as the conduit between these groups, RTP obtains and distills the various viewpoints and perspectives of one constituency and delivers them effectively to another. Whether it is relaying research leader opinion to community practitioners or patient preferences to clinical researchers, RTP’s role in promoting cross talk and communication between these diverse entities enhances understanding and ultimately positively affects patient care.

The success of the RTP model is directly related to Dr Love, RTP’s team of experienced clinicians and a support staff skilled in delivering relevant content across many instructional formats. The wealth of knowledge and acumen of this team enables the company to work in many medical education arenas and therapeutic areas including breast cancer, colorectal cancer, lung cancer, prostate cancer, renal cell cancer and non-Hodgkin's lymphoma.